Trinity Biotech plc (NASDAQ:TRIB) Short Interest Down 17.1% in December

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 58,500 shares, a decrease of 17.1% from the November 30th total of 70,600 shares. Based on an average trading volume of 173,800 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.5% of the company’s stock are short sold.

Trinity Biotech Price Performance

TRIB opened at $0.89 on Tuesday. Trinity Biotech has a fifty-two week low of $0.75 and a fifty-two week high of $3.55. The firm has a market capitalization of $6.75 million, a P/E ratio of -0.39 and a beta of 0.97. The company’s 50-day moving average is $1.26 and its 200 day moving average is $1.84.

Institutional Investors Weigh In On Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its stake in shares of Trinity Biotech plc (NASDAQ:TRIB) by 7.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 359,810 shares of the company’s stock after buying an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned about 4.72% of Trinity Biotech worth $390,000 as of its most recent SEC filing. 78.97% of the stock is currently owned by institutional investors.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.